Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback